Mechanistic convergence and shared therapeutic targets in Niemann‐Pick disease. Issue 3 (5th December 2019)

• Record Type: Journal Article
• Authors: Colaco, Alexandria; Kaya, Ecem; Adriaenssens, Elias; Davis, Lianne C.; Zampieri, Stefania; Fernández‐Suárez, María E.; Tan, Chong Y.; Deegan, Patrick B.; Porter, Forbes D.; Galione, Antony; Bembi, Bruno; Dardis, Andrea; Platt, Frances M.
• Is Part Of: Journal of inherited metabolic disease. Volume 43:Issue 3(2020)
• Page Start: 574
• Page End: 585
• Publication Date: 2019-12-05
• Subjects: ABCA1 -- lysosome -- Niemann‐Pick disease type C -- substrate reduction therapy -- Tangier disease; Metabolism, Inborn errors of -- Periodicals; Metabolism -- Disorders -- Periodicals; 616.39042
• DOI: 10.1002/jimd.12191
• Languages: English
• ISSNs: 0141-8955

Abstract

Abstract: Niemann‐Pick disease type C (NPC) and Tangier disease are genetically and clinically distinct rare inborn errors of metabolism. NPC is caused by defects in either NPC1 or NPC2 ; whereas Tangier disease is caused by a defect in ABCA1 . Tangier disease is currently without therapy, whereas NPC can be treated with miglustat, a small molecule inhibitor of glycosphingolipid biosynthesis that slows the neurological course of the disease. When a Tangier disease patient was misdiagnosed with NPC and treated with miglustat, her symptoms improved. This prompted us to consider whether there is mechanistic convergence between these two apparently unrelated rare inherited metabolic diseases. In this study, we found that when ABCA1 is defective (Tangier disease) there is secondary inhibition of the NPC disease pathway, linking these two diseases at the level of cellular pathophysiology. In addition, this study further supports the hypothesis that miglustat, as well as other substrate reduction therapies, may be potential therapeutic agents for treating Tangier disease as fibroblasts from multiple Tangier patients were corrected by miglustat treatment.